# OnCo record edgewood-oncology (company). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/companies/edgewood-oncology/>
  a schema:Organization ;
  onco:kind "company" ;
  schema:identifier "edgewood-oncology" ;
  schema:name "Edgewood Oncology"@en ;
  schema:description "Edgewood Oncology is developing BTX-A51, a pill that blocks three enzymes cancer cells rely on, for acute myeloid leukaemia, a genetically defined form of breast cancer and liposarcoma."@en ;
  schema:url <https://onco.cc/companies/edgewood-oncology/>, <https://www.edgewoodoncology.com/> ;
  schema:dateModified "2026-10-29"^^xsd:date ;
  schema:citation <https://www.edgewoodoncology.com/>, <https://www.edgewoodoncology.com/news/edgewood-oncology-emerges-from-stealth-with-20-million-in-series-a-financing-to-advance-btx-a51-in-patients-with-hematologic-malignancies-and-genetically-defined-solid-tumorsnbsp> ;
  schema:addressCountry "US" ;
  onco:cancers <https://onco.cc/cancers/aml/>, <https://onco.cc/cancers/breast-cancer/>, <https://onco.cc/cancers/liposarcoma/> ;
  onco:sections <https://onco.cc/fronts/targeted-therapy/> ;
  onco:technologies <https://onco.cc/technologies/kinase-inhibitors/> ;
  onco:targets <https://onco.cc/targets/csnk1a1/>, <https://onco.cc/targets/cdk9/> .